Late dysphagia, xerostomia, and submucosal fibrosis following concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a prospective comparison of intensity-modulated radiotherapy and three-dimensional conformal radiotherapy
DOI:
https://doi.org/10.18203/2320-6012.ijrms20262356Keywords:
3D-CRT, Concurrent chemoradiotherapy, Dysphagia, Head and neck cancer, IMRT, XerostomiaAbstract
Background: Late radiation-induced toxicities remain an important cause of long-term morbidity in survivors of locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Intensity-modulated radiotherapy (IMRT) offers improved dose conformity and normal tissue sparing compared with three-dimensional conformal radiotherapy (3D-CRT). This study compared late toxicity outcomes following definitive concurrent chemoradiotherapy delivered using IMRT versus 3D-CRT.
Methods: This prospective observational study enrolled patients with LA-HNSCC treated with definitive concurrent chemoradiotherapy between September 2017 and December 2018. Seventy-eight evaluable patients (39 IMRT, 39 3D-CRT) were analysed. Late xerostomia, dysphagia, and submucosal fibrosis were graded at 12 months using RTOG/EORTC late radiation morbidity scoring criteria.
Results: Clinically significant xerostomia (grade ≥2) occurred in 23.1% of patients treated with IMRT compared with 51.3% of those treated with 3D-CRT (p=0.019). IMRT was associated with a 55% reduction in the risk of xerostomia (RR 0.45, 95% CI 0.24-0.86). Grade ≥2 dysphagia was observed in 61.5% of patients in the IMRT group and 64.1% in the 3D-CRT group (p=1.000), while grade ≥2 submucosal fibrosis occurred in 30.8% and 43.6%, respectively (p=0.349). Patients treated with IMRT also had fewer treatment interruptions and lower rates of clinically significant weight loss.
Conclusions: IMRT was associated with a significantly lower incidence of late xerostomia than 3D-CRT in patients with LA-HNSCC undergoing definitive concurrent chemoradiotherapy. Although differences in dysphagia and submucosal fibrosis were not statistically significant, the overall toxicity profile favoured IMRT. These findings support IMRT as the preferred radiotherapy technique for reducing long-term treatment-related morbidity in head and neck cancer.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49.
Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6(1):92.
Pignon JP, le Maître A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomized trials and 17,346 patients. Radiother Oncol. 2009;92(1):4-14.
Langendijk JA, Doornaert P, Rietveld DH, Leemans CR, Aaronson NK, Slotman BJ. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol. 2008;26(22):3770-6.
Grégoire V, Mackie TR. State of the art on dose prescription, reporting and recording in intensity-modulated radiation therapy (ICRU report no. 83). Cancer Radiother. 2011;15(6-7):555-9.
Gupta T, Agarwal JP, Master Z, Murthy V, Budrukkar A, Laskar SG, et al. Randomized trial of parotid-sparing intensity-modulated radiotherapy versus conventional radiotherapy in head and neck cancer: long-term results of salivary function and quality of life. Radiother Oncol. 2012;104(3):343-7.
Nutting CM, Morden JP, Harrington KJ. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011;12(2):127-36.
Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. Evaluation of Chemotherapeutic Agents. New York: Columbia University Press; 1949:191-205.
Grégoire V, Mackie TR, De Neve W, Gospodarowicz M, Purdy JA, van Herk M, et al. Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT): the ICRU report 83. J ICRU. 2010;10(1):1-106.
Bentzen SM, Constine LS, Deasy JO. Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S3-9.
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341-6.
Pow EH, Kwong DL, McMillan AS, Wong MC, Sham JS, Leung LH, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys. 2006;66(4):981-91.
Marta GN, Silva V, de Andrade Carvalho H. Intensity-modulated radiation therapy for head and neck cancer: systematic review and meta-analysis. Radiother Oncol. 2014;110(1):9-15.
Deasy JO, Moiseenko V, Marks L, Chao KS, Nam J, Eisbruch A. Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S58-63.
Eisbruch A, Schwartz M, Rasch C. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared? Int J Radiat Oncol Biol Phys. 2004;60(5):1425-39.
Jensen K, Lambertsen K, Grau C. Late swallowing dysfunction and dysphagia after radiotherapy for pharynx cancer: frequency, intensity and correlation with dose and volume parameters. Radiother Oncol. 2007;85(1):74-82.
Nguyen NP, Moltz CC, Frank C. Dysphagia following chemoradiation for locally advanced head and neck cancer. Ann Oncol. 2004;15(3):383-8.
Delanian S, Lefaix JL. The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway. Radiother Oncol. 2004;73(2):119-31.
Bese NS, Hendry J, Jeremic B. Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys. 2007;68(3):654-61.
Downloads
Published
How to Cite
Issue
Section
